Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

55.90 -0.82 (-1.45%)

Official Closing Price Updated: 7:00 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

85 86 Next >

What's going on in today's session: S&P500 movers ↗

May 15, 2025

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.

Via Chartmill

What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocks ↗

May 15, 2025

Via The Motley Fool

Topics Economy Government

Stay informed with the top movers within the S&P500 index on Wednesday. ↗

May 14, 2025

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session.

Via Chartmill

Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030 ↗

May 14, 2025

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.

Via Benzinga

CMS Expands Medicare Drug Price Talks To Part B Meds In 2026 Shake Up ↗

May 14, 2025

CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26.

Via Benzinga

Bristol-Myers Squibb Strikes $350 Million Deal To End Hawaii's Plavix Lawsuit ↗

May 13, 2025

Bristol-Myers Squibb will pay $350 million to settle Hawaii's lawsuit over Plavix marketing practices, ending claims without admitting wrongdoing and avoiding trial.

Via Benzinga

Topics Lawsuit

Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News ↗

May 13, 2025

It's biggest product will be up for price negotiations under the Inflation Reduction Act much sooner than expected.

Via Investor's Business Daily

Topics Economy Government

Market Monitor News May 12 ( NRG Energy, Amazon, Meta Platforms UP - CVS Health DOWN) ↗

May 13, 2025

Wall Street surges sharply as US-China tariff cuts drive tech stocks higher; pharma sector gains on new Trump drug pricing initiative.

Via Chartmill

Topics Government World Trade

Merck, Pfizer, Eli Lilly Stocks Rebound As Trump Targets Drug Costs With New Executive Order ↗

May 12, 2025

The U.S. President said that Big Pharma would either voluntarily abide by this principle or the federal government will use its power to ensure the U.S. pays the same price as other countries.

Via Stocktwits

Topics Government

S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform ↗

May 12, 2025

It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices.

Via Investor's Business Daily

Topics Government Stocks

EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients ↗

May 12, 2025

Lantern Pharma receives FDA clearance to begin Phase 1b/2 trial of LP-184 in advanced NSCLC patients with key mutations and low PD-L1 expression.

Via Benzinga

Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots ↗

May 12, 2025

Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space.

Via Benzinga

Topics Artificial Intelligence

BMY Q1 Earnings Call: Growth Portfolio Offsets Declines, Guidance Raised Amid Pipeline Advancements

May 12, 2025

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 5.6% year on year to $11.2 billion. The company’s...

Via StockStory

Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket ↗

May 12, 2025

What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription...

Via Benzinga

Topics Government

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) stands out as a stock that provides good value for the fundamentals it showcases. ↗

May 09, 2025

BRISTOL-MYERS SQUIBB CO has a stellar value proposition. NYSE:BMY not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.

Via Chartmill

3 Healthcare Stocks in Hot Water

May 09, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...

Via StockStory

Topics Economy Stocks

A Look Into Bristol-Myers Squibb Inc's Price Over Earnings ↗

May 08, 2025

Via Benzinga

Top gainers and losers in the S&P500 index during Wednesday's after-hours session. ↗

May 07, 2025

After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers.

Via Chartmill

FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight ↗

May 06, 2025

FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing.

Via Benzinga

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

May 06, 2025

Via Benzinga

Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

May 06, 2025

From Bristol Myers Squibb

Via Business Wire

FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months ↗

May 02, 2025

FDA extended the aficamten decision deadline to Dec. 26 after classifying the REMS submission as a major amendment to the NDA review.

Via Benzinga

1 Stock Under $50 with Solid Fundamentals and 2 to Keep Off Your Radar

May 02, 2025

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...

Via StockStory

Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Stock Worth Considering ↗

April 30, 2025

Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Stock Worth Considering

Via Chartmill

This High-Yield Pharma Stock Looks Like an Incredible Bargain ↗

April 30, 2025

Via The Motley Fool

Topics Intellectual Property

Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet

April 29, 2025

Recent upticks in the market may disguise the ongoing risks that remain for investors; these factors point to the importance of a defensive strategy.

Via MarketBeat

Topics Economy Government World Trade

Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom ↗

April 28, 2025

Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising...

Via Talk Markets

Topics ETFs Stocks / Equities

Top 3 Health Care Stocks That May Rocket Higher In April ↗

April 28, 2025

Via Benzinga

Pfizer (PFE) Reports Q1: Everything You Need To Know Ahead Of Earnings

April 28, 2025

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings tomorrow before market hours. Here’s what you need to know.

Via StockStory

Topics Government World Trade

4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off ↗

April 26, 2025

Via The Motley Fool

Topics Economy Intellectual Property World Trade

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

85 86 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Bristol-Myers Squibb (NY:BMY)

All News about Bristol-Myers Squibb

Starting at $3.75/week.

Subscribe Today